TAFI made stickier. Blood 2012 Apr 12;119(15):3380-1
Date
04/14/2012Pubmed ID
22500053DOI
10.1182/blood-2012-02-406652Scopus ID
2-s2.0-84859856443 (requires institutional sign-in at Scopus site) 1 CitationAbstract
Bleeding in hemophilia is the result of factor VIII/IX deficiency with corresponding reduced thrombin production and enhanced fibrinolysis secondary to lower thrombin activatable fibrinolysis inhibitor (TAFI) production. Factor replacement is the cornerstone of hemophilia treatment but is often not possible in developing countries.
Author List
Abshire TAuthor
Thomas Abshire MD Emeritus Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsBlood Coagulation
Dog Diseases
Hemophilia A
Humans
Receptors, Thrombin
Recombinant Proteins









